Date: 2015-03-27
Type of information: Private placement
Company: Adocia (France)
Investors: US-based specialized healthcare investors
Amount: €32 million
Funding type: private placement
Planned used: The funds will be used to fund research and development and general corporate purposes.
Others: * On March 27, 2015, Adocia announced that it has raised €31.96m in gross proceeds through a private placement of new shares. Adocia placed a total of 621,887 new shares of €0.10 nominal value each with domestic and healthcare specialist investors at a price of €51.40, representing a 5.17% discount to the volume weighted average price of the Adocia share on the regulated market of Euronext in Paris over the three trading days before pricing. The new shares represent 10% of the current number of outstanding shares and will bring the total number of shares after the issue to 6,840,763. Jefferies International Limited and Leerink Partners LLC are acting as Joint Bookrunners for the private placement and LifeSci Capital LLC as Co-Lead Manager. To support and grow its development, a subsidiary has also been created in USA. Simon Bruce, Medical Director and Stephen Daly, General Manager joined the subsidiary in March 2015.
Therapeutic area: Metabolic diseases
